Cardiovascular risk, hypertension, and NSAIDs

Current Pain and Headache Reports

Volumn 11, Issue 6, 2007, Pages 428-435

  White, William B ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROPIONIC ACID DERIVATIVE; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; ROFECOXIB; VERAPAMIL;

ANTIINFLAMMATORY ACTIVITY; ARTERIAL PRESSURE; ARTHRITIS; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLON POLYP; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONGESTIVE HEART FAILURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; OBSERVATIONAL STUDY; OSTEOARTHRITIS; PERIPHERAL EDEMA; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; HYPERTENSION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK;

EID: 36849018363     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-007-0229-x     Document Type: Review

References (72)

1. Silverstein FE, Faich G, Goldstein JL, et al: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000, 284:1247-1255.
2. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343:1520-1528.
3. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286:954-959.
4. Konstam MA, Weir MR, Reicin A, et al.: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001, 104:2280-2288.
5. Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092-1102.
6. Nussmeier NA, Whelton AA, Brown MT, et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352:1081-1091.
7. Gilroy DW, Colville-Nash PR, Willis D, et al.: Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999, 5:698-701.
8. Kiefer W, Dannhardt G: Novel insights and therapeutic applications in the field of inhibitors of COX-2. Curr Med Chem 2004, 11:3147-3161.
9. Fosslien E: Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000, 37:431-502.
10. Hao CM, Breyer MD: Hypertension and cyclooxygenase inhibitors. Target: The renal medulla. Hypertension 2004, 44:396-397.
11. Harris RC, Zhang MZ, Cheng HF: Cyclooxygenase-2 and the renal angiotensin system. Acta Physiol Scand 2004, 181:543-547.
12. Fries S, Grosser T: The cardiovascular pharmacology of COX-2 inhibition. Hematology Am Soc Hematol Educ Program 2005:445-51.
13. Rudic RD, Brinster D, Cheng Y, et al.: COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 2005, 96:1240-1247.
14. Egan KM, Wang M, Lucin MB, et al.: Cyclooxygenases, thromboxane, and atherosclerosis: Plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005, 111:334-342.
15. Francois H, Athirakul K, Howell D, et al.: Prostacyclin protects againsts elevated blood pressure and cardiac fibrosis. Cell Metab 2005, 2:201-207.
16. Rabausch K, Bretscbneider E, Sarbia M, et al.: Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2 derived Prostaglandins. Circ Res 2005, 96:e1-e6.
17. Bolli R, Shinmura K, Tang XL: Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of pre-conditioning. Cardiovasc Res 2002, 55:506-519.
18. Antman EM, DeMets D, Loscalzo J: Cyclooxygenase inhibition and CV risk. Circulation 2005, 112:759-770.
19. Virdis A, Colucci R, Fornai M, et al.: Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: Role of inducible nitric-oxide synthase and oxidative stress. J Pharmacol Exp Ther 2005, 312:945-953.
20. Steffel J, Hermann M, Greutert H, et al.: Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 2005, 111:1685-1689.
21. Sowers JR, White WB, Pitt B, et al.: The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis and type 2 diabetes. Arch Intern Med 2005, 165:161-168.
22. Pope JE, Anderson JJ, Felson DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993, 153:477-484.
23. Johnson AG, Nguyen TV, Day RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994, 121:289-300.
24. Grover SA, Coupal L, Zowall H: Treating osteoarthritis with cyclooxygenase-2 specific inhibitors: What are the benefits of avoiding blood pressure destabilization? Hypertension 2005, 45:92-97.
25. White WB: Benefits of antihypertensive therapy in older patients with hypertension. Arch Intern Med 2000, 160:149-150.
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000, 283:1967-1975.
27. Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high CV risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031.
28. Morgan TO, Anderson A, Bertram D: Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 2000, 13:1161-1167.
29. Schwartz JI, Vandormael K, Malice MP, et al.: Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002, 72:50-61.
30. Simon LS, Smolen JS, Abramson SB, et al.: Controversies in COX-2 selective inhibition. J Rheumatol 2002, 29:1501-1510.
31. Brater DC: Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 1999, 107:65S-70S.
32. Whelton A, Schulman G, Wallemark C, et al.: Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000, 160:1465-1470.
33. Whelton A, White WB, Bello AE, et al.: Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002, 90:959-963.
34. Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999, 106(5B):13S-24S.
35. Qi Z, Hao CM, Langenbach RI, et al.: Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 2002, 110:61-69.
36. Hermann M, Camici G, Fratton A, et al.: Differential effects of selecctive cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003, 108:2308-2311.
37. Hermann M, Shaw S, Kiss E, et al.: Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. Hypertension 2005, 45:193-197.
38. Hinz B, Dormann H, Brune K: More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 2006, 54:282-291.
39. Winner LK, Elliot DJ, Miners JO, Knights KM: In vitro glucoronidation of aldosterone by human liver and kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UCT) 287: inhibition by non-steroidal anti-inflammatory drugs (NSAIDs). Proc Aust Soc Clin Exp Pharmacol Toxicol 2005, 11: P2-02.
40. Knights KM, Mangoni AA, Minors JO: Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime? Br J Clin Pharmacol 2006, 61:738-740.
41. White WB, Kent J, Taylor A, et al.: Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002, 39:929-934.
42. Izhar M, Alausa T, Folker A, et al.: Effects of COX-inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension 2004, 43:574-577.
43. Houston MC, Weir M, Gray J, et al.: The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995, 155:1049-1054.
44. Mamdani M, Juurlink DN, Lee DS, et al.: Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004, 363:1751-1756.
45. White WB, Faich G, Whelton A, et al.: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002, 89:425-430.
46. White WB, Faich G, Borer JS, Makuch RW: CV thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003, 92:411-418.
47. White WB, West CR, Borer JS, et al.: Risk of CV events in patients receiving celecoxib. A metanalysis of randomized clinical trials. Am J Cardiol 2006, in press.
48. Collaborative overview of randomized trials of antiplatelet therapy: I: prevention of death, myocardial infarction, and stroke. Antiplatelet Trialists' Collaboration. BMJ 1994, 308:81-106.
49. Farkouh ME, Kirshner H, Harrington RA, et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004, 364:675-684.
50. Graham DJ, Campen D, Hui R, et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365:475-481.
51. Gislason GH, Jacobsen S, Rasmussen JN, et al.: Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective non-steroidal antiinflammatory drugs after acute infarction. Circulation 2006, 113:2906-2913.
52. McGettigan P, Henry D: Cardiovascular risk and inhibition of cyclooxygenases: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygcnase-2. JAMA 2006, 296:1633-1644.
53. Chan AT, Manson JE, Albert CM, et al.: Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006, 113:1578-1587.
54. Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-1080.
55. Bertagnolli MM, Eagle CJ, Zauber AG, et al.: Celecoxib for the prevention of colorectal adenomas. N Engl J Med 2006, 355:873-884.
56. Arber N, Eagle CJ, Spicak J, et al.: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355:885-895.
57. Singh G, Mithal A, Triadafilopoulos G: Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient not the drug class. Ann Rheum Dis 2005, 64(Suppl III):85.
58. Sturkenboom MC, Dieleman J, Verhamme K, et al.: Cardiovascular events during use of COX-2 selective and non-selective NSAIDs. Pharmacoepidemiol Drug Saf 2005, 14:S57.
59. Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclooxygenase inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005, 330:1366-1372.
60. Johnsen SP, Larsson H, Tarone RE, et al.: Risk of hospitalisation for myocardial infarction among users of rofecoxib, celecoxib and other NSAIDs: a population based case control study. Arch Intern Med 2005, 165:978-984.
61. Levesque LE, Brophy JM, Zhang B: The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005, 142b:481-489.
62. Kimmel SE, Berlin JA, Reilly M, et al.: The effects of non-selective non-aspirin non-steroidal anti-inflammatory medications on the risk of non-fatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 2004, 43:985-990.
63. Kimmel SE, Berlin JA, Reilly M, et al.: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005, 142:157-164.
64. Ray WA, Stein CM, Daugherty JR, et al.: Cyclo-oxygenase-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002, 360:1071-1073.
65. Ray WA, Stein CM, Hall K, et al.: Non-steroidal anti-inflammatory drugs and the risk of serious coronary heart disease: an observational cohort study. Lancet 2002, 359:118-123.
66. Fischer LM, Schlienger RG, Matter CM, et al.: Discontinuation of non-steroidal anti-inflammatory drug therapy and the risk of acute myocardial infarction. Arch Intern Med 2004, 164: 2472-2476.
67. Garcia Rodriguez LA, Gonzalez-Perez A: Long-term use of traditional of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med 2005, 3:17.
68. Bak S, Andersen M, Tsiropoulos I, et al.: Risk of stroke associated with non-steroidal anti-inflammatory drugs. Stroke 2003, 34:379-386.
69. Solomon DH, Glynn RJ, Levin R, Avorn J: Non-steroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002, 162:1099-1104.
70. Schlienger RG, Jick H, Meier CR: Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol 2002, 54:327-332.
71. Watson DJ, Rhodes T, Cai B, Guess HA: Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002, 162:1105-1110.
72. MacDonald TM, Wei L: Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003, 361:573-574.